First, the small sample size of non-serous carcinoma and FIGO I-II in our study biased the research results; Second, rare studies between ACAT2 expression and chemo-response further confirmed our conclusions; Third, we failed to thoroughly explore the mechanism of ACAT2 overexpression leading to chemo-resistance, which would be our next research purpose; Last, more large-scale studies are needed to validate the relationship between ACAT2 expression and chemo-response in the future. The gene discussed is ACAT2; the disease is serous adenocarcinoma.